629 related articles for article (PubMed ID: 15823769)
1. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
2. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
[TBL] [Abstract][Full Text] [Related]
3. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
4. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Hendrix CW; Jackson KA; Whitmore E; Guidos A; Kretzer R; Liss CM; Shah LP; Khoo KC; McLane J; Trapnell CB
Clin Pharmacol Ther; 2004 May; 75(5):464-75. PubMed ID: 15116059
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR
Clin Pharmacol Ther; 1998 Dec; 64(6):597-602. PubMed ID: 9871424
[TBL] [Abstract][Full Text] [Related]
6. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra C; Li J; March B; O'Mara E
Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Scheffler MR; Colburn W; Kook KA; Thomas SD
Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
[TBL] [Abstract][Full Text] [Related]
8. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
9. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Yu Z; Yu D; Walker PS; Tang-Liu DD
Clin Pharmacokinet; 2004; 43(10):673-84. PubMed ID: 15244497
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.
Lin WH; Feng HP; Shadle CR; O'Reilly T; Wagner JA; Butterton JR
Eur J Clin Pharmacol; 2014 Sep; 70(9):1107-13. PubMed ID: 24992979
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
12. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Roy P; Jakate AS; Patel A; Abramowitz W; Wangsa J; Persiani S; Kapil R
J Clin Pharmacol; 2005 Mar; 45(3):329-36. PubMed ID: 15703367
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers.
Moore KH; McNeal S; Britto MR; Bye C; Sale M; Richardson MS
Clin Ther; 2002 Nov; 24(11):1887-901. PubMed ID: 12501881
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.
Sidhu J; Job S; Singh S; Philipson R
Br J Clin Pharmacol; 2006 Feb; 61(2):191-9. PubMed ID: 16433873
[TBL] [Abstract][Full Text] [Related]
17. Dirithromycin increases ethinyl estradiol clearance without allowing ovulation.
Wermeling DP; Chandler MH; Sides GD; Collins D; Muse KN
Obstet Gynecol; 1995 Jul; 86(1):78-84. PubMed ID: 7784027
[TBL] [Abstract][Full Text] [Related]
18. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
19. Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis.
Zhang X; Rowell L; Fettner S; Lau C; Teuber D
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):27-38. PubMed ID: 24161161
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
Garg V; van Heeswijk R; Yang Y; Kauffman R; Smith F; Adda N
J Clin Pharmacol; 2012 Oct; 52(10):1574-83. PubMed ID: 22039291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
